Mayo Clinic in Rochester
Rochester, Minnesota, 55905, United States
Location status: Recruiting
Location contact
Clinical Trials Referral Office
CONTACT
Ronald S. Go, M.D.
PRINCIPAL_INVESTIGATOR
Recruiting
NCT Number: NCT06331377
Clinical and Molecular Characteristics of Histiocytic Disorders
This study is being done to collect medical and personal histories as well as a samples of blood, other body fluid and/or tumor/disease tissue for current and future research studies on histiocytic disorders.
Recruiting
Interested in participating?
Request InfoKey information
Conditions
Age range
1 year and older
Sex eligibility
All sexes
Study type
Observational
Primary location
About this study
PRIMARY OBJECTIVES:
I. Define molecular signature and genomic landscape of histiocytic disorders. II. Correlate genomic findings with transcriptional abnormalities. III. Identify promising prognostic alterations and potential therapeutic targets.
OUTLINE: This is an observational study.
Patients complete questionnaires and undergo blood and tissue sample collection. Patients' medical records are also reviewed.
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- * All patients diagnosed with histiocytic disorders and age ≥1 year
Exclusion criteria
- * < 1 years age
Treatment and study plan
Non-Interventional Study
OtherNon-interventional study
Primary outcomes
-
Identify molecular markers
Time frame: Baseline
Biopsy samples will be analyzed for the presence of molecular markers associated with histiocytic disorders. Potential markers include BRAF V600E, cyclinD1, PD-L1, p16, and p53.6. For any test results that are actionable, patients will be notified and the results will be available in the electronic medical record.
-
Change in PD-L1 and T-cell Bim expression
Time frame: Baseline; post-treatment (estimated up to 2 years, potentially 4 times per year)
Blood testing will be performed for soluble PD-L1 and T-cell Bim expressions before and after radiation therapy for histiocytic disease to assess change in levels and role of immunotherapy. For any test results that are actionable, patients will be notified and the results will be available in the electronic medical record.
Sponsors and collaborators
Lead sponsor
Mayo Clinic
Other
Registry information
Important dates
- Study start
- 2017
- Primary completion
- 2027
- Study completion
- 2027
- First posted
- Mar 26, 2024
- Registry last updated
- Sep 9, 2025
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.